Plaque Psoriasis With Obesity Or Overweight
LLYEli Lilly & CompanyCatalyst overview
Research summary
This catalyst tracks a Phase 3 update for Taltz + Zepbound (Combination Therapy) in Plaque Psoriasis With Obesity Or Overweight. The expected timing is based on the latest available company guidance and may change.
01/08/26:- TOGETHER-PsO Ph3b trial in psoriasis with obesity; topline results in H1 2026. 02/18/26:- TOGETHER-PsO Ph3b 36-week topline met primary and key secondary endpoints; detailed results to follow.
Verification
Confirm timing and program details against the company announcement or filing.